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Tobacco smoking is a well-established risk factor for multiple sclerosis (MS) onset, 
progression, and poor health outcomes in people with MS. Despite smoking being a 
modifiable risk factor, no research has been undertaken to understand how, or who 
is best placed, to assess or understand smoking behaviour in people with MS, or 
how healthcare professionals can best assist people with MS to quit. People with MS 
may have unique motivators to continue smoking, or unique barriers to smoking 
cessation, that are not addressed by existing cessation tools. Research is urgently 
needed in this area if the aim is to maximise health outcomes for all people with MS.  
 
Introduction  
Multiple sclerosis (MS) is a chronic neurological condition with no known cause, 
although evidence suggests it occurs due to genetic vulnerability coupled with 
environmental factors1. The manifestations of the disease are heterogeneous, 
although common symptoms include fatigue, sensory disturbances, muscle 
weakness, and cognitive impairment. Following a diagnosis of MS, often early in 
adulthood, a person experiences uncertainty about the expected course of their 
disease and impact on their future. While there are more than a dozen disease 
modifying therapies for people with relapsing remitting MS (RRMS), pharmacological 
treatment for people with progressive disease is limited with one approved therapy 
for primary progressive MS and none for secondary progressive MS (SPMS) without 
relapses. None of these therapies provide 100% efficacy.2 Recent developments of 
new and repurposed drugs, and new biomarkers to monitor progression, show 
promising results for future treatment of MS2. However, few treatments specifically 
target neurodegeneration and none reverse damage in the central nervous system. 
Unfortunately, most people with MS still experience accumulation of disabling 
symptoms over the course of the disease3.  
 
A recent topical review in the Multiple Sclerosis Journal highlighted the role of 
tobacco smoking as a key determinant of MS onset, increasing the risk by 
approximately 50%.4 Observational cross-sectional and cohort studies show that 
modifiable lifestyle or health risk factors, including tobacco smoking, but also 
sedentary behaviour, obesity and low serum vitamin D levels, are associated with 
disability worsening.5 This suggests the potential to modify risk factors and improve 
health outcomes for people with MS.6 
 
Tobacco smoking and health outcomes 
 A meta-analysis of 8 datasets showed that smokers had an increased hazard ratio of 
1.55 (95% confidence interval (CI) 1.1, 2.2) for faster progression compared to non-
smokers. The authors concluded that although the evidence was of moderate quality 
due to heterogeneity, smoking is an important modifiable risk factor for MS 
progression.5 Smoking is also associated with lower quality of life,7 increased 
depression and anxiety8 and higher premature mortality.9 A prospective study of 
more than 900 people with MS showed that the hazard ratio for death in smokers 
compared to never smokers was 2.7 (95%CI 1.6 to 4.6). Further, the standardised 
mortality ratio for smokers with MS was 1.8 (95%CI 1.2, 2.7) compared with smokers 
without MS, while there was no difference between non-smokers with or without MS.9 
Smoking may also adversely impact on the efficacy of disease modifying drugs.10, 11 
Quitting smoking has significant benefits for people with MS. Persistent smokers 
reached the progressive stage of MS eight years earlier compared with those who 
quit at time of diagnosis, accelerating time from RRMS to SPMS by 4.7% (95% CI 
2.3-7.2) for each successive year smoked.12 Another study showed that smoking 
cessation significantly reduces the risk of reaching disability milestones, and the 
earlier people with MS or clinically isolated syndrome (CIS) quit, the stronger this 
effect (risk reduction is approximately 30% per 10 years).13 Given that increased 
disability leads to exponentially higher economic costs in MS,14 lowering smoking 
rates may lead to substantial economic benefits, in addition to improvements to 
health outcomes and quality of life. Economic modelling for people with Crohn’s 
disease, another chronic immune relapsing-remitting disorder, shows cost 
effectiveness and improved health outcomes of all potential smoking cessation 
strategies over no strategy15. Further, smoking cessation could decrease the risk of 
MS in family members who may be genetically susceptible for developing MS, a risk 
further increased by being exposed to passive smoking.16 Indeed, the risk of 
childhood-onset MS is reduced in children whose parent stops smoking.17   
 
As smoking is a key risk factor for MS onset, it is not surprising that smoking rates 
are high at time of diagnosis. A UK study reported that 49% of 895 people smoked at 
time of MS diagnosis, with 22% still smoking 17 years later.18 Whether smoking 
remains more prevalent among people with MS compared to people with other 
chronic disease, or the general population is not well studied. However, some data 
from case-control studies suggests this is the case. An Australian case-control study 
of 282 people with first demyelinating event and 558 controls matched on age, sex 
and study region reported that 27.4% of people with MS smoked at time of enrolment 
versus 22.4% of controls,19 with 25.6% of people with MS still smoking 5 years 
 later.20 Data from a case-control study from Sweden also suggests that people with 
MS are more likely to smoke than controls matched for age, sex, and residential 
area; 36.5% of 902 people with MS vs 28.6% of 1855 controls.21 In addition, the 
increasing interest in cannabis to manage MS symptoms (one in five use cannabis 
regularly in the UK and Canada) may further increase the use of tobacco,22 as 
smoking a mix of tobacco and cannabis is common (although more evidence is 
needed in this area). It is a cause for considerable concern that around 20% of 
people with MS smoke cigarettes regularly, given the adverse consequences. We 
currently do not know what the barriers are to smoking cessation, what the 
motivators are to continue to smoke, whether people with MS are aware of the extent 
to which smoking contributes to their health outcomes, and what their needs are to 
receive smoking cessation assistance.  
 
MS-specific motivators and barriers  
It is possible that there are MS-specific motivators to continue smoking, as well as 
MS-specific barriers to smoking cessation and that interventions designed for the 
general population are not meeting the needs of people with MS. Some motivators 
may be similar to those in other chronic disease populations (e.g. stress, boredom, 
coping, self-medication, perceived pain relief), while some may be unique to MS.23, 24 
For people with acute health problems, the motivation to change behaviour should  
be higher, but if their health condition presents unique challenges that prevent them 
from quitting successfully,25 many will find themselves unable to quit unless these 
challenges are adequately addressed. Several common symptoms such as cognitive 
dysfunction,26 pain and depression27 may be both motivators to continue smoking, 
and barriers to sustained smoking cessation. While smoking tobacco is harmful, 
nicotine may have actual and/or perceived benefits for symptoms,21, 28 as has been 
found in people with schizophrenia29 and depression,30 and in animal models for 
MS.31 Evidence from Swedish snuff users (smokeless tobacco) suggests that it is not 
the nicotine in tobacco that is responsible for an increased chance of MS onset, but 
other elements in the smoke.21 One key issue that is likely important with MS, and 
may be for some other conditions, is the role of nicotine. Nicotine may ameliorate 
deficits in cognitive function such as inhibitory control, which can be impaired 
following abstinence.32 Similarly, depressive symptoms reduce cessation success25 
and there is a complex relationship between cognitive function, coping and 
depression in people with MS.33, 34 Finally, there is a clear association between 
smoking and pain,35 which has been summarized as a positive feedback loop where 
smoking may be a risk factor for pain, while pain is a powerful motivator to continue 
 smoking due to anti-nociceptive effects.36 These feedback loops may be especially 
hard to break for people experiencing depression or anxiety who may have increased 
pain sensitivity (all common symptoms in MS) when attempting smoking cessation.37 
If indeed nicotine is actually or perceived to be helping with these issues, then this is 
likely to be one area where providing cessation assistance for those with MS may 
differ to the generic advice provided for all smokers. They also point to a potentially 
important role for nicotine replacement products. However, we have been unable to 
find any studies on the role of nicotine in ameliorating MS symptoms. In addition to 
the potential role of nicotine, there may be other disease specific barriers, but this 
has not been investigated. We need to understand what additional or augmented 
resources people with MS may need (if any) on top of generic smoking cessation 




Calls have been made for smoking cessation to be urgently advised to people with 
MS.6, 13, 38, 39 At present we do not know to what extent people with MS receive 
assessment, advice and assistance by health professionals to quit smoking, but 
there is some evidence of an unmet need40. We currently do not know whether MS 
clinicians, or other health professionals are aware of the specific consequences of 
smoking on MS health outcomes, or if they feel able or willing to assist people with 
MS to quit smoking. The most effective method to offer smoking assessment and 
cessation intervention is also unclear (e.g. through a general practitioner, MS nurse, 
or neurologist). Anecdotally, time, resource or knowledge barriers may exist for 
health practitioners to assess smoking behaviour, refer to, or provide interventions. 
Further, there may be a lack of confidence that existing smoking cessation 
interventions or tools available are effective for people with MS, which may be true to 
a degree if such interventions miss important MS-specific issues. Understanding 
current knowledge and practice, including gaps and barriers to assessing and 
addressing smoking from a healthcare provider perspective are essential in guideline 
or intervention development. Important aspects that need to be considered include: 
assessing smoking behaviour, referring for intervention, delivering the intervention 
and follow-up; the best method, which healthcare professional is best placed, and 
when the best time is for each of these steps. From the perspective of the person 
with MS, there may be disease and sociodemographic considerations for smoking 
cessation management, such as whether people with specific symptoms, e.g. 
cognitive impairment, depression or pain, require different levels of provider support. 
 The answers to these questions may differ between countries depending on the 
structure of the healthcare system and/or access to generic smoking cessation 
programmes.  
 
Tailored smoking cessation interventions  
In many other areas of health, tailoring basic smoking cessation interventions to 
include a focus on comorbidities or problem-specific barriers are showing evidence of 
improving outcomes. Interventions that are tailored to specific groups, and take into 
account social determinants, may be more successful in promoting cessation, e.g. 
tailoring to people with low literacy.41 For example, a customised intervention, 
including behavioural therapy and nicotine replacement therapy (NRT) is effective in 
people with cardiovascular disease42 and cancer.43 While for people with psychotic 
illness, 8 sessions of intensive clinician-delivered therapies in combination with NRT 
were effective in a dose-response manner44 and in chronic obstructive pulmonary 
disease interventions with specific behaviour change techniques were found to be 
most efficacious.45 It has been suggested that a combination of NRT and behavioural 
mood management should be considered for people with depression, although more 
evidence is needed to confirm efficacy.46 It is troubling that nothing is happening to 
provide similar interventions tailored for our priority population, those with (or at risk 
of) MS.  
 
Tailoring interventions to people with MS 
Despite the known risks for health outcomes and premature mortality, not one study 
of an intervention for smoking cessation has been undertaken in people with MS or 
CIS.42, 45, 47 One smoking cessation trial was designed in 2012,48 but this was halted 
due to a combination of recruitment difficulties including lack of interest in quitting, 
and funding restrictions (personal communication, J Ciccolo 2017). The dearth of 
research into this key modifiable risk factor is in stark contrast to other modifiable risk 
factors such as physical inactivity and low vitamin D, where dozens of studies 
including meta-analyses are published. 
 
Future research in this area needs to address the following questions: 
 Are people with MS more likely to smoke than people with other chronic 
disease or the general population? 
 Are people with MS, especially smokers, aware of the additional risks of 
smoking for their MS? 
  Are there MS/CIS-specific motivators for smoking behaviour? In particular 
what is the role of nicotine? 
 Are there MS/CIS-specific barriers to smoking cessation? In particular, do 
specific MS symptoms impact cessation success? 
 To what extent is smoking behaviour routinely assessed and addressed in 
clinical practice? 
 What is the best method to assess smoking behaviour and refer people for 
smoking cessation? 
 To what extent is the MS health workforce aware of the importance of 
smoking cessation for people with MS? 
 Which healthcare provider is best placed to provide assessment and or 
cessation intervention? 
 When (and how often) is the best time to assess, refer or intervene? 
 To what extent are existing smoking cessation interventions effective in 
people with MS? 
 Should and can existing smoking cessation interventions be adapted to better 
meet the needs of people with MS and CIS? 
Given the paucity of evidence in the area currently, the priority would be to 
understand what MS/CIS-specific barriers to smoking cessation exist, and what 
barriers from healthcare professionals exist in assessing and referring for smoking 
cessation. This will enable learnings from smoking cessation research in other areas 
to be adapted and applied to the development of guidelines and interventions to be 
tested for efficacy in people with MS.  
 
Challenges  
There may be challenges in recruiting smokers for smoking cessation intervention 
studies, highlighting the importance of assessing the feasibility and acceptability of 
interventions, prior to phase III effectiveness trials. Smokers newly diagnosed with 
MS may be highly motivated to take action if made aware of the implications of the 
diagnosis and the evidence that smoking speeds progression. Combinations of the 
use of telephone Quitlines and online resources can help overcome challenges of 
accessing people with MS across a broad geographic region and in remote areas. 
Involvement of MS clinicians including neurologists, MS nurses and/or general 
practitioners are crucial to drive clinical change, depending on the healthcare setting. 
Models where MS clinicians work with smoking cessation experts to deliver high 
quality integrated services are possible, and these are increasingly being used by 
 Quitlines to help support groups requiring more than standard levels of assistance.49, 
50 Efforts to design and test smoking cessation interventions for priority groups are 
considered the last frontier in tobacco control in countries with low smoking rates 
such as Australia.51 The savings to economic and healthcare costs, improvements to 
health outcomes and quality of life could be substantial given people often live with 
MS for 3-5 decades following diagnosis. This would justify intense interventions, as in 
other chronic disease15.  
 
Conclusion 
Despite compelling evidence that smoking is a key risk factor for development, 
unfavourable health outcomes and premature mortality in people with MS, there is 
little focus in research or clinical practice on smoking cessation. There is an urgent 
need to understand whether there are MS-specific barriers for smoking cessation, 
whether there are real or perceived benefits from smoking or nicotine on MS 
symptoms, and what best practice is around assessing and addressing smoking in 
people with MS.  We present this topical review to MS and smoking cessation 
researchers, as well as relevant funding bodies, to highlight that much needed 
research in this key modifiable lifestyle factor is required if we are to maximise health 
outcomes for all people with MS. 
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